<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585218</url>
  </required_header>
  <id_info>
    <org_study_id>175519021995</org_study_id>
    <nct_id>NCT03585218</nct_id>
  </id_info>
  <brief_title>Women With Breast Cancer Undergoing Chemotherapy: Implications in Quality of Life</brief_title>
  <official_title>Clinical, Emotional, Cognitive and Neuropsychophysiological Impact of a Hedonic Aroma in Women With Breast Cancer Undergoing Chemotherapy: Implications in Quality of Life.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minho</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer (BC) triggers a myriad of physical and psychosocial stressors with
      repercussions on quality of life (QoL). The present study is a pioneering Randomized
      Controlled Trial (RCT) in Portugal, seeking to study the impact of a hedonic aroma during
      chemotherapy in women with breast cancer (3, 6 and 9 weeks, and 3 months upon concluding
      chemotherapy). To do this, the participants will be randomly assigned to one of the groups.
      The experimental group will be exposed to chemotherapy along with a hedonic scent, while the
      control group will only be exposed to chemotherapy. Both groups will be evaluated at the
      level of psychological morbidity, disease representation, coping, executive function,
      cortisol levels, severity of treatment effects and QoL.The aim of this study is to evaluate
      the impact of a hedonic aroma on the clinical, emotional and neurocognitive variables that
      contribute to reduce the side effects of chemotherapy and promote QoL in women with BC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sample was non-probabilistic, consisting of 51 participants in the control group (CG) and
      51 in the experimental group (EG), necessary to detect a difference of 10 points between the
      groups (standard deviation = 18), in EORCT QLQ- C30, for a power of 80% and a significant
      level of 5%.

      Five moments of evaluation: T0 (baseline: oncology consultation before AQ), T1 (3 weeks after
      QT onset - 2nd Cycle), T2 (6 weeks - 3rd Cycle), T3 (9 weeks - 4th Cycle) and T4 (3 months
      upon concluding QT) (Annex 3 - Flowchart). These moments were chosen taking into account the
      classes of drugs used in AQ. Each cycle has an interregnum of 21 or 14 days, depending on the
      AQ protocol used. Randomized and controlled clinical study (RCT), single blind (the
      participant does not know to which group belongs, only the investigator) and longitudinal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Actual">April 4, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>On each moment of data collection, the researcher will apply the evaluation protocol to the participant regardless of the group. Regarding the psychophysiological variable, each participant's saliva will be collected using salivettesÂ®, while cortisol concentrations will be analyzed through ELISA kits. At baseline, each participant will be provided with three salivettes and an explanatory leaflet so that, on the day before the 2nd Cycle (T1), they can collect their own saliva, around 23 hours before (lowest peak of the cortisol circle), and on the day of the fasting QT, on waking up and thirty minutes after waking up (highest peak of the cortisol circle and assessing reactivity). This process will be replicated throughout the remaining evaluation moments. Subsequently, it is also our goal to evaluate the cortisol levels due to QT by performing one collection of saliva before QT and another thirty minutes after QT.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>When a participant is eligible, according to the inclusion criteria, it is allocated to one of the groups, according to the order of entry in the study and with alternation by groups, in a ratio of 1:1.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>Change in baseline Anxiety and Depression in the 4th cycle of chemotherapy (Time 3 - 63 days after the start of chemotherapy) and follow up (Time 4 - 3 months after chemotherapy ends)</time_frame>
    <description>assessment instruments: Hospital Anxiety and Depression Scale (HADS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distress</measure>
    <time_frame>Change in baseline Distress in the 4th cycle of chemotherapy (Time 3 - 63 days after the start of chemotherapy) and follow up (Time 4 - 3 months after chemotherapy ends)</time_frame>
    <description>Emotions Thermometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The experimental group presented, in comparison to the control group, lower blood pressure</measure>
    <time_frame>Change in the experimental group in the blood pressure of the 1st cycle (each cycle occurs every 21 days) compared to the other cycles of chemotherapy where they inhale the essential oils: up to 63 days.</time_frame>
    <description>blood pressure measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The experimental group presented, in comparison to the control group, lower level of cortisol concentration</measure>
    <time_frame>Change in the experimental group in the blood pressure of the 1st cycle (each cycle occurs every 21 days) compared to the other cycles of chemotherapy where they inhale the essential oils: up to 63 days.</time_frame>
    <description>saliva collection and biochemical analysis of cortisol through ELISA kits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The experimental group presented, in comparison to the control group, lower level of side effects</measure>
    <time_frame>Change in baseline QLQ BR23 baseline scores for follow up (3 months after completion of chemotherapy treatment) in the experimental group.</time_frame>
    <description>assessment instruments: the EORTC QLQ-BR23 (European Organisation for Research and Treatment of Cancer - Quality of Life, Module for Breast Cancer). interpretation of the results, the higher the value obtained, lower the quality of life, except in questions 14, 15 and 16 where: the higher the score, the better the quality of life evaluated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The experimental group presented, in comparison to the control group, lower level of quality of life</measure>
    <time_frame>Change in baseline QLQ C30 baseline scores for follow up (3 months after completion of chemotherapy treatment) in the experimental group.</time_frame>
    <description>Assessment instruments: the European Organisation for Research and Treatment of Cancer - Quality of Life (EORTC QLQ-C30). Interpretation of the results, the higher the value obtained, the better the total quality of life - total quality of life result, through weighting formulas carried out by the European Organization for Research and Treatment of Cancer (EORTC) (http://groups.eortc.be/qol/manuals)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group is not subject to intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inhalation of essential oils</intervention_name>
    <description>Intervention &quot;Inhalation of essential oils&quot;: From the T1 (2nd Cycle QT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the QT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with BC in stages 0-2;

          -  level 0-2 on the Zubrod scale,

          -  without cognitive impairment,

          -  adjuvant chemotherapy (AQ) treatment.

        Exclusion Criteria:

          -  Severe mental disturbance;

          -  olfactory impairment (â¤6), evaluated at baseline through the instrument smell
             diskettes and only in the EG participants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Pereira, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minho</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Pereira, Master</last_name>
    <phone>934577699</phone>
    <phone_ext>+351</phone_ext>
    <email>martinha.marquespereira@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GraÃ§a Pereira, PhD</last_name>
    <phone>938471039</phone>
    <phone_ext>+351</phone_ext>
    <email>gracep@psi.uminho.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AntÃ³nio FradÃ£o</name>
      <address>
        <city>Viana Do Castelo</city>
        <state>Estrada De Santa Luzia</state>
        <zip>4904-858</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AntÃ³nio FradÃ£o, graduation</last_name>
      <phone>258 802 108</phone>
      <phone_ext>+351</phone_ext>
      <email>internato.mgf@ulsam.min-saude.pt</email>
    </contact>
    <contact_backup>
      <last_name>LuÃ­sa Azevedo, graduation</last_name>
      <phone>258 802 100</phone>
      <phone_ext>+351</phone_ext>
      <email>luisa.azevedo@ulsam.min-saude.pt</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <reference>
    <citation>Den Oudsten BL, Van Heck GL, Van der Steeg AF, Roukema JA, De Vries J. Predictors of depressive symptoms 12 months after surgical treatment of early-stage breast cancer. Psychooncology. 2009 Nov;18(11):1230-7. doi: 10.1002/pon.1518.</citation>
    <PMID>19142843</PMID>
  </reference>
  <reference>
    <citation>Bidstrup PE, Christensen J, Mertz BG, Rottmann N, Dalton SO, Johansen C. Trajectories of distress, anxiety, and depression among women with breast cancer: Looking beyond the mean. Acta Oncol. 2015 May;54(5):789-96. doi: 10.3109/0284186X.2014.1002571. Epub 2015 Mar 11.</citation>
    <PMID>25761086</PMID>
  </reference>
  <reference>
    <citation>Lam WW, Shing YT, Bonanno GA, Mancini AD, Fielding R. Distress trajectories at the first year diagnosis of breast cancer in relation to 6 years survivorship. Psychooncology. 2012 Jan;21(1):90-9. doi: 10.1002/pon.1876. Epub 2010 Dec 2.</citation>
    <PMID>21132676</PMID>
  </reference>
  <reference>
    <citation>Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013 Jul;14(8):721-32. doi: 10.1016/S1470-2045(13)70244-4. Epub 2013 Jun 5. Review.</citation>
    <PMID>23759376</PMID>
  </reference>
  <reference>
    <citation>Knobf T. Breast Cancer. In: Holland JC, Breitbart WS, Butow PN, Jacobsen PB, Loscalzo MJ, McCorkle R, editors. Psycho-Oncology. New York: Oxford University Press; 2012. p. 134-154.</citation>
  </reference>
  <reference>
    <citation>Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, Gralow J. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008 Mar-Apr;30(2):112-26. doi: 10.1016/j.genhosppsych.2007.10.008. Review.</citation>
    <PMID>18291293</PMID>
  </reference>
  <reference>
    <citation>Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000 Jun 21;92(12):994-1000.</citation>
    <PMID>10861311</PMID>
  </reference>
  <reference>
    <citation>Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Future Oncol. 2010 Dec;6(12):1863-81. doi: 10.2217/fon.10.142. Review.</citation>
    <PMID>21142861</PMID>
  </reference>
  <reference>
    <citation>Millar K, Purushotham AD, McLatchie E, George WD, Murray GD. A 1-year prospective study of individual variation in distress, and illness perceptions, after treatment for breast cancer. J Psychosom Res. 2005 Apr;58(4):335-42.</citation>
    <PMID>15992569</PMID>
  </reference>
  <reference>
    <citation>Rozema H, VÃ¶llink T, Lechner L. The role of illness representations in coping and health of patients treated for breast cancer. Psychooncology. 2009 Aug;18(8):849-57. doi: 10.1002/pon.1488.</citation>
    <PMID>19085973</PMID>
  </reference>
  <reference>
    <citation>Ahadi H, Delavar A, Rostami AM. Comparing Coping Styles in Cancer Patients and Healthy Subjects. Procedia Soc Behav Sci. 2014 Feb; 116(21):3467 - 3470. doi:10.1016/j.sbspro.2014.01.785.</citation>
  </reference>
  <reference>
    <citation>Khalili N, Farajzadegan Z, Mokarian F, Bahrami F. Coping strategies, quality of life and pain in women with breast cancer. Iran J Nurs Midwifery Res. 2013 Mar;18(2):105-11.</citation>
    <PMID>23983738</PMID>
  </reference>
  <reference>
    <citation>Andreotti C, Root JC, Schagen SB, McDonald BC, Saykin AJ, Atkinson TM, Li Y, Ahles TA. Reliable change in neuropsychological assessment of breast cancer survivors. Psychooncology. 2016 Jan;25(1):43-50. doi: 10.1002/pon.3799. Epub 2015 Mar 23.</citation>
    <PMID>25808921</PMID>
  </reference>
  <reference>
    <citation>Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006 Feb;20(1):76-89.</citation>
    <PMID>16410227</PMID>
  </reference>
  <reference>
    <citation>Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008 Feb;17(2):122-30.</citation>
    <PMID>17518411</PMID>
  </reference>
  <reference>
    <citation>Andryszak P. Izdebski P. Tujakowski J. [The influence of adjuvant chemotherapy on cognitive functioning of women with breast cancer - a literature review]. Nowotwory. Journal of Oncology 2012;62(4):291-304.</citation>
  </reference>
  <reference>
    <citation>Moore HC. An overview of chemotherapy-related cognitive dysfunction, or 'chemobrain'. Oncology (Williston Park). 2014 Sep;28(9):797-804. Review.</citation>
    <PMID>25224480</PMID>
  </reference>
  <reference>
    <citation>Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep. 2012 Jun;12(3):267-75. doi: 10.1007/s11910-012-0264-9. Review. Erratum in: Curr Neurol Neurosci Rep. 2012 Jun;12(3):340.</citation>
    <PMID>22453825</PMID>
  </reference>
  <reference>
    <citation>Li L, Yang Y, He J, Yi J, Wang Y, Zhang J, Zhu X. Emotional suppression and depressive symptoms in women newly diagnosed with early breast cancer. BMC Womens Health. 2015 Oct 24;15:91. doi: 10.1186/s12905-015-0254-6.</citation>
    <PMID>26497200</PMID>
  </reference>
  <reference>
    <citation>Catani M, Dell'acqua F, Thiebaut de Schotten M. A revised limbic system model for memory, emotion and behaviour. Neurosci Biobehav Rev. 2013 Sep;37(8):1724-37. doi: 10.1016/j.neubiorev.2013.07.001. Epub 2013 Jul 9. Review.</citation>
    <PMID>23850593</PMID>
  </reference>
  <reference>
    <citation>Krusemark EA, Li W. Enhanced Olfactory Sensory Perception of Threat in Anxiety: An Event-Related fMRI Study. Chemosens Percept. 2012 Mar 1;5(1):37-45. Epub 2012 Jan 10.</citation>
    <PMID>22866182</PMID>
  </reference>
  <reference>
    <citation>Angelucci FL, Silva VV, Dal Pizzol C, Spir LG, Praes CE, Maibach H. Physiological effect of olfactory stimuli inhalation in humans: an overview. Int J Cosmet Sci. 2014 Apr;36(2):117-23. doi: 10.1111/ics.12096. Epub 2014 Jan 7. Review.</citation>
    <PMID>24117755</PMID>
  </reference>
  <reference>
    <citation>Kamen C, Tejani MA, Chandwani K, Janelsins M, Peoples AR, Roscoe JA, Morrow GR. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol. 2014 Jan 5;722:172-9. doi: 10.1016/j.ejphar.2013.09.071. Epub 2013 Oct 21. Review.</citation>
    <PMID>24157982</PMID>
  </reference>
  <reference>
    <citation>Villemure C, Slotnick BM, Bushnell MC. Effects of odors on pain perception: deciphering the roles of emotion and attention. Pain. 2003 Nov;106(1-2):101-8.</citation>
    <PMID>14581116</PMID>
  </reference>
  <reference>
    <citation>Hess LM, Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. Oncol Nurs Forum. 2007 Sep;34(5):981-94. Review.</citation>
    <PMID>17878127</PMID>
  </reference>
  <reference>
    <citation>Lazarus RS, Folkman S. Transactional theory and research on emotions and coping. Eur J Pers. 1987;1(3):141-169. https://doi.org/10.1002/per.2410010304</citation>
  </reference>
  <reference>
    <citation>Stone AA, Schwartz JE, Smyth J, Kirschbaum C, Cohen S, Hellhammer D, Grossman S. Individual differences in the diurnal cycle of salivary free cortisol: a replication of flattened cycles for some individuals. Psychoneuroendocrinology. 2001 Apr;26(3):295-306.</citation>
    <PMID>11166492</PMID>
  </reference>
  <reference>
    <citation>Cohen MZ, White L. Cancer-Related Distress. In: Yarbro CH, Wujcik D, Gobel BH, editors. Cancer nursing: Principles and practice. Burlington, MA: Jones &amp; Bartlett Learning; 2016. p. 759 - 779</citation>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Minho</investigator_affiliation>
    <investigator_full_name>Marta Alexandra Marques Pereira</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Essentials Oils</keyword>
  <keyword>Adjuvant Chemotherapy</keyword>
  <keyword>Salivary cortisol</keyword>
  <keyword>Neuropsychophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Only cortisol values will be shared with other researchers in the field of oncology medicine for them to analyze the relationship between cortisol levels and the side effects reported by participants during chemotherapy treatment.</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be available in February 2020 and will be available for 5 years.</ipd_time_frame>
    <ipd_access_criteria>The data will be shared with the collaborators involved in the research, for biochemical analysis (ELISA Kit -IBL) and statistics (SPSS Software). The principal investigator will be responsible for reviewing requests.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

